These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 8537362)

  • 1. Effects of non-nucleoside inhibitors of human immunodeficiency virus type 1 in cell-free recombinant reverse transcriptase assays.
    Gu Z; Quan Y; Li Z; Arts EJ; Wainberg MA
    J Biol Chem; 1995 Dec; 270(52):31046-51. PubMed ID: 8537362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies of neutralizing monoclonal antibody to human immunodeficiency virus type 1 reverse transcriptase: antagonistic and synergistic effects in reactions performed in the presence of nucleoside and nonnucleoside inhibitors, respectively.
    Gu Z; Li X; Quan Y; Parniak MA; Wainberg MA
    J Virol; 1996 Apr; 70(4):2620-6. PubMed ID: 8642696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Site-specific incorporation of nucleoside analogs by HIV-1 reverse transcriptase and the template grip mutant P157S. Template interactions influence substrate recognition at the polymerase active site.
    Klarmann GJ; Smith RA; Schinazi RF; North TW; Preston BD
    J Biol Chem; 2000 Jan; 275(1):359-66. PubMed ID: 10617626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-nucleoside inhibitors of HIV-1 reverse transcriptase inhibit phosphorolysis and resensitize the 3'-azido-3'-deoxythymidine (AZT)-resistant polymerase to AZT-5'-triphosphate.
    Odriozola L; Cruchaga C; Andréola M; Dollé V; Nguyen CH; Tarrago-Litvak L; Pérez-Mediavilla A; Martínez-Irujo JJ
    J Biol Chem; 2003 Oct; 278(43):42710-6. PubMed ID: 12917424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutated K65R recombinant reverse transcriptase of human immunodeficiency virus type 1 shows diminished chain termination in the presence of 2',3'-dideoxycytidine 5'-triphosphate and other drugs.
    Gu Z; Arts EJ; Parniak MA; Wainberg MA
    Proc Natl Acad Sci U S A; 1995 Mar; 92(7):2760-4. PubMed ID: 7535930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a human immunodeficiency virus-1 in vitro DNA synthesis system to study reverse transcriptase inhibitors.
    Borroto-Esoda K; Boone LR
    Antiviral Res; 1994 Apr; 23(3-4):235-49. PubMed ID: 7519003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of 3'-deoxynucleoside 5'-triphosphate concentrations on chain termination by nucleoside analogs during human immunodeficiency virus type 1 reverse transcription of minus-strand strong-stop DNA.
    Arts EJ; Marois JP; Gu Z; Le Grice SF; Wainberg MA
    J Virol; 1996 Feb; 70(2):712-20. PubMed ID: 8551607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiological Mg
    Achuthan V; Singh K; DeStefano JJ
    Biochemistry; 2017 Jan; 56(1):33-46. PubMed ID: 27936595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular basis for the enantioselectivity of HIV-1 reverse transcriptase: role of the 3'-hydroxyl group of the L-(beta)-ribose in chiral discrimination between D- and L-enantiomers of deoxy- and dideoxy-nucleoside triphosphate analogs.
    Maga G; Amacker M; Hübscher U; Gosselin G; Imbach JL; Mathé C; Faraj A; Sommadossi JP; Spadari S
    Nucleic Acids Res; 1999 Feb; 27(4):972-8. PubMed ID: 9927728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nucleoside analog resistance caused by insertions in the fingers of human immunodeficiency virus type 1 reverse transcriptase involves ATP-mediated excision.
    Boyer PL; Sarafianos SG; Arnold E; Hughes SH
    J Virol; 2002 Sep; 76(18):9143-51. PubMed ID: 12186898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzymatic properties of two mutants of reverse transcriptase of human immunodeficiency virus type 1 (tyrosine 181-->isoleucine and tyrosine 188-->leucine), resistant to nonnucleoside inhibitors.
    Loya S; Bakhanashvili M; Tal R; Hughes SH; Boyer PL; Hizi A
    AIDS Res Hum Retroviruses; 1994 Aug; 10(8):939-46. PubMed ID: 7529032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dissecting the effects of DNA polymerase and ribonuclease H inhibitor combinations on HIV-1 reverse-transcriptase activities.
    Shaw-Reid CA; Feuston B; Munshi V; Getty K; Krueger J; Hazuda DJ; Parniak MA; Miller MD; Lewis D
    Biochemistry; 2005 Feb; 44(5):1595-606. PubMed ID: 15683243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of the amino acid in the human immunodeficiency virus type 1 reverse transcriptase involved in the pyrophosphate binding of antiviral nucleoside triphosphate analogs and phosphonoformate. Implications for multiple drug resistance.
    Im GJ; Tramontano E; Gonzalez CJ; Cheng YC
    Biochem Pharmacol; 1993 Dec; 46(12):2307-13. PubMed ID: 7506027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric HIV-1 and feline immunodeficiency virus reverse transcriptases: critical role of the p51 subunit in the structural integrity of heterodimeric lentiviral DNA polymerases.
    Amacker M; Hübscher U
    J Mol Biol; 1998 May; 278(4):757-65. PubMed ID: 9614940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitory effect of N3-methyl derivative of 3'-azido-3'-deoxythymidine 5'-triphosphate on the activity of HIV-1 reverse transcriptase.
    Nakane H; Suzuki A; Nakata Y; Kitade Y; Hirota K; Maki Y; Ono K
    Nucleic Acids Symp Ser; 1991; (25):27-8. PubMed ID: 1726810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Colorimetric assays for evaluation of the mode of action of human immunodeficiency virus type 1 non-nucleoside reverse transcriptase inhibitors.
    Shao X; Rytting AS; Ekstrand DH; Vrang L; Källander CF; Gronowitz JS
    Antivir Chem Chemother; 1998 Mar; 9(2):167-76. PubMed ID: 9875388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric human immunodeficiency virus type 1 and feline immunodeficiency virus reverse transcriptases: role of the subunits in resistance/sensitivity to non-nucleoside reverse transcriptase inhibitors.
    Auwerx J; North TW; Preston BD; Klarmann GJ; De Clercq E; Balzarini J
    Mol Pharmacol; 2002 Feb; 61(2):400-6. PubMed ID: 11809865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potentiation of inhibition of wild-type and mutant human immunodeficiency virus type 1 reverse transcriptases by combinations of nonnucleoside inhibitors and d- and L-(beta)-dideoxynucleoside triphosphate analogs.
    Maga G; Hübscher U; Pregnolato M; Ubiali D; Gosselin G; Spadari S
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1192-200. PubMed ID: 11257034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of synergy in the inhibition of HIV-1 reverse transcriptase by combinations of the 5'-triphosphates of various anti-HIV nucleoside analogs.
    White EL; Parker WB; Ross LJ; Shannon WM
    Antiviral Res; 1993 Dec; 22(4):295-308. PubMed ID: 7506513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human immunodeficiency virus type 1 reverse transcriptase. 3'-Azidodeoxythymidine 5'-triphosphate inhibition indicates two-step binding for template-primer.
    Jaju M; Beard WA; Wilson SH
    J Biol Chem; 1995 Apr; 270(17):9740-7. PubMed ID: 7537269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.